

## ABSTRACT

It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I<sub>2</sub> agonist, EP<sub>2</sub> agonist and EP<sub>4</sub> agonist. Since prostaglandin (PG) I<sub>2</sub> agonist, EP<sub>2</sub> agonist or EP<sub>4</sub> agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, *etc.*) and various cell and organ diseases.